TRB Chemedica AG

What TRB Chemedica AG does

TRB Chemedica AG is the German operating subsidiary of the family-owned Swiss TRB Chemedica Group, headquartered in Geneva with its German center of competence established in 1996 in Feldkirchen near Munich. The company specializes in hyaluronic acid (HA)-based medical devices and pharmaceuticals serving two therapeutic verticals: ophthalmology/eye care and orthopedics/joint health. Its product portfolio spans preservative-free eye drops (VISMED®, HYLOVIS®, RELYS®), intra-articular HA injections for osteoarthritis (OSTENIL® family, HAXL ONE), lid care products (including the October 2025-launched IDROFLOG®), and complementary food supplements, supported by proprietary technology platforms including sT-LysYal® supramolecular chemistry and the PRGF-ENDORET® autologous plasma growth factor system. Manufacturing is conducted in Switzerland, Brazil, and Argentina, with operations spanning 18 directly-served subsidiaries and more than 70 distribution markets globally, supported by over 1,000 employees.

The business operates a sales-led go-to-market model targeting ophthalmologists and orthopedists, with prescription and OTC products distributed primarily through pharmacies in Germany and the Benelux region and via local distributor networks elsewhere. Revenue is generated through high-volume, transactional sales of branded specialty pharma products across mass-prevalence conditions (dry eye, osteoarthritis) rather than through concentrated enterprise contracts, and the company holds ISO 13485, EU MDR, and GDP certifications. Leadership transitioned in January 2025 following the death of founder Dr. Guido di Napoli; current management includes board members Hans Kalkbrenner and Isaac Abad, with Jens Horstkotte chairing the supervisory board. The company is privately held by the founding family and does not publicly disclose financial results.

Name

TRB Chemedica AG

Legal name

TRB Chemedica AG

Website

https://trbchemedica.de

Company type

Private

Founded year

1996

Operating status

Operating

Short description

TRB Chemedica AG is the German subsidiary of family-owned Swiss TRB Chemedica Group, developing and marketing hyaluronic acid-based medical devices and pharmaceuticals for ophthalmology and orthopedics across 18 countries with 1,000+ employees.

Ownership category

akta.pro rank

Headquarters

HQ city

Feldkirchen

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Prescription and OTC pharmaceutical products for ophthalmology including glaucoma treatments, anti-inflammatory drops, and dry eye treatments. Multiple drug products including Bapiri®, Dimaz®, Ketazed®, Lifog®, Ophtesic®, Oratoria®, Tidimaz®, Iricryn®.
2. Medical Devices: Medical device products including hyaluronic acid-based eye drops (VISMED®, RELYS®, HYLOVIS®), orthopedic injectables (OSTENIL® family, HAXL ONE), and lid care products (ILAST®). Sold through pharmacies and directly to patients.
3. Food Supplements: Nutritional supplements including OMEGA-3 TRB®, ARTILANE® (hyaluronic acid + collagen + vitamin C), and CALCIPROTECT® (calcium + vitamins D3 and K1).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

TRB Chemedica AG develops, manufactures and markets hyaluronic acid-based medical devices, prescription ophthalmic pharmaceuticals and food supplements primarily for ophthalmology (dry eye, glaucoma, allergies, corneal edema, inflammation) and orthopedics (osteoarthritis, tendon disorders, post-arthroscopy joint fluid replacement). The company owns manufacturing facilities in Switzerland, Brazil and Argentina, and operates as the group's center of competence for HA product approvals, quality management and global safety surveillance. It sells through pharmacies, online pharmacies, direct professional sales to ophthalmologists and orthopedists, and 18 wholly-owned subsidiaries spanning Europe, Latin America and Asia-Pacific.

Product overview

TRB Chemedica AG is a pharmaceutical and medical device company specializing in ophthalmology and orthopedics. The portfolio consists of two main divisions: (1) Ophthalmology products including VISMED® family (hyaluronic acid eye drops in various formulations - standard, multi-dose, gel, gel multi-dose, light), HYLOVIS® LIPO (hyaluronic acid with lipids), RELYS® (with sT-LysYal®), REMOGEN® OMEGA (with omega-3), VISLUBE® (for contact lenses), ILAST® line (lid care products), ODM 5® (for corneal edema), PRGF-ENDORET® (biological tissue regeneration), OMEGA-3 TRB® supplement, and prescription medications (Ketazed®, Ophtesic®, Oratoria®, Dimaz®, Tidimaz®, Iricryn®, Bapiri®, Lifog®); (2) Orthopedics products featuring OSTENIL® family (1% and 2% hyaluronic acid injections for large and small joints), HAXL ONE (cross-linked hyaluronic acid for knee), OSTENIL® TENDON (for tendinopathies), O_Cure® (PRP treatment), VISCOSEAL® SYRINGE (synovial fluid replacement), and dietary supplements ARTILANE® and CALCIPROTECT®.

Differentiator

Problem solved

Functional benefit

Brands

• VISMED: Hyaluronic acid eye drops for dry eyes - therapy standard for over 25 years
• OSTENIL
• RELYS
• HYLOVIS
• IDROFLOG
• VISLUBE
• ILAST
• ODM 5
• PRGF-ENDORET
• HAXL ONE
• VISCOSEAL
• O_Cure
• ARTILANE
• CALCIPROTECT
• Ketazed
• VISMED GEL-THINK PINK

Quantifiable outcome

• 1 in 5 ophthalmology patients in Germany suffer from dry eye syndrome
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Brustkrebs Deutschland e.V.coreOthersCharitable partnership for breast cancer awareness. TRB Chemedica supports the organization through VISMED® GEL-THINK PINK! campaign, donating 2€ per activity and providing VISMED® GEL samples for 'wellness packages'. Received 51,392€ donation in 2019 (third largest donation in association's history).
• mediaPoolminorImplementation/ SI/ Consulting PartnerDesign, programming, and hosting provider for TRB Chemedica website located in Munich.
• DocCheckminorChannel Partner/ Reseller/ DistributorHealthcare professional login gateway for TRB Chemedica's professional-only information portal (Fachkreise section).

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Regional players

• Carl Zeiss Meditec: Germany-based medical technology company focused on ophthalmology diagnostics, surgical devices, and consumables. Adjacent peer serving the same ophthalmology specialist customer base as TRB Chemedica, but in devices rather than pharmaceuticals.

Broad incumbents

• Bausch + Lomb: Large global ophthalmology company with pharmaceutical, surgical, and consumer eye care products. Competes with TRB Chemedica across ophthalmic pharmaceuticals (including dry eye and allergy drops) and OTC eye care.
• Santen Pharmaceutical: Japanese-headquartered specialty ophthalmology pharma with strong presence in Europe (Santen GmbH). Direct overlap with TRB Chemedica in prescription ophthalmic pharmaceuticals (glaucoma, inflammation, allergy) and dry-eye treatments.
• Alcon: Global ophthalmology leader offering surgical, pharmaceutical (including dry eye), and vision care products. Overlaps with TRB Chemedica in dry-eye and ophthalmic pharmaceuticals but at vastly larger scale and broader portfolio.

Direct peers

• Laboratoires Théa: French family-owned specialty ophthalmology pharma with a broad portfolio of eye drops, lid care, and dry eye products across Europe. Directly comparable to TRB Chemedica in target customers (ophthalmologists), therapeutic focus (dry eye, glaucoma, allergy), and mid-sized European specialty pharma profile.
• IBSA Farmaceutici: Swiss specialty pharma with strong hyaluronic acid franchises in osteoarthritis (Sinovial) and ophthalmology (drops for dry eye). Comparable to TRB Chemedica in HA-based viscoelastic technology, European specialty positioning, and Switzerland-headquartered profile.
• Anika Therapeutics: US-based specialty company focused on hyaluronic acid-based viscosupplementation (Monovisc, Orthovisc) and regenerative solutions. Closely comparable to TRB Chemedica's orthopedic OSTENIL/HAXL ONE/VISCOSEAL franchise in product, indication, and route-to-market via orthopedists.
• Fidia Farmaceutici: Italian specialty pharma specializing in hyaluronic acid-based products for joint health (viscosupplementation) and ophthalmology, with own manufacturing. Directly comparable to TRB Chemedica's OSTENIL/VISCOSEAL orthopedic HA portfolio and HA manufacturing competence.
• Seikagaku Corporation: Japanese specialty pharma built around hyaluronic acid for joint disease (intra-articular injections) and ophthalmology (dry eye surgery aids). Highly comparable to TRB Chemedica's hyaluronic acid manufacturing and orthopedic HA injectables business.

Emerging players

• Bioventus: US-based orthopedic specialty company with hyaluronic acid (Durolane) and biologic/pain therapies for osteoarthritis. Comparable to TRB Chemedica's orthopedic franchise in indication (OA), HA modality, and orthopedist-targeted sales motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@HilfebeiTrockenenAugen
• Facebookfacebook.com/VISMED.de
• LinkedInlinkedin.com/company/trb-chemedica-ag
• Instagraminstagram.com/vismed.de

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRB Chemedica AG